Chugai Pharmaceutical Co., Ltd. (CHGCF)

32.43 0.00 (0.00%) At close: 03:40PM EDT

Chugai Pharmaceutical Co., Ltd.

2-1-1 Nihonbashi-Muromachi
Chuo 103-8324
Japan
81 3 3281 6611
https://www.chugai-pharm.co.jp

Sector(s): Healthcare
Industry: Drug Manufacturers - General
Full-time employees: 7,604

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Osamu Okuda	President, CEO & Representative Director	1.39M	N/A	1963
Mr. Toshiaki Itagaki	Head of Finance Supervisory Division, CFO & Executive VP	N/A	N/A	1960
Toshiya Sasai	Executive of Investor Relations Group & Corporate Communications Department	N/A	N/A	N/A
Mr. Shinji Hidaka	Executive VP and Head of Marketing & Sales Division	N/A	N/A	N/A
Mr. Junichi Ebihara	Executive Vice President	N/A	N/A	N/A
Dr. Yoshiaki Ohashi	SVP & Full-time Audit Supervisory Board Member	N/A	N/A	1960
Mr. Tetsuya Yamaguchi	Executive VP and Head of Project, Lifecycle Management & Foundation Medicine Unit	N/A	N/A	N/A
Mr. Yoshiyuki Yano	Executive Vice President	N/A	N/A	N/A
Ms. Satoko Shisai	Executive VP & Head of Digital Transformation Unit	N/A	N/A	1963
Dr. Shigehiro Yamada Ph.D.	Head of Sustainability Department and Full-Time Audit & Supervisory Board Member	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances and collaboration with Roche Group. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.

Corporate governance

Chugai Pharmaceutical Co., Ltd.’s ISS governance QualityScore as of 29 April 2024 is 6. The pillar scores are Audit: 1; Board: 7; Shareholder rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.